Close
Achema middle east
swop processing & packaging

Medicago wins European patent for influenza virus-like particles in plants

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Barrier Packaging Solutions for Biopharmaceuticals

Advanced Barrier Packaging for Sensitive Biopharmaceuticals The biopharmaceutical industry has...

AI-Powered Quality Control for Pharma Packaging

AI-Powered Quality Control in Pharmaceutical Packaging The pharmaceutical industry has...

Robotics in High-Speed Pharma Packaging Lines

Robotics and Automation in High-Speed Pharma Packaging The pharmaceutical industry...

Digital Twin Solutions for Pharma Packaging

Digital Twin Applications Optimizing Pharma Packaging Lines The pharmaceutical industry...

The European Patent Office (EPO) has granted Medicago a patent protecting exclusive rights to produce influenza virus-like particles (VLPs) in plants through July 2028.

Patent titled ‘Influenza virus-like particles (VLPs) comprising hemagglutinin produced within a plant’ was originally filed by the biopharmaceutical company on 11 July 2008.

Medicago business development vice president Frederic Ors said as the company expands the development of influenza vaccine programs, the coverage offered by the patent strengthens its position.

“Additionally, we believe the patent enhances our IP position and further illustrates our competitive advantage with respect to the development of VLPs and other recombinant proteins in plants,” Ors added.

“In our opinion, our innovative method of rapidly producing efficacious influenza VLPs is a required technology for strengthened protection of the population against biological threats.”

The company’s IP portfolio currently comprises more than 500 patents and patent applications protecting in over 45 countries.

 

Latest stories

Related stories

Barrier Packaging Solutions for Biopharmaceuticals

Advanced Barrier Packaging for Sensitive Biopharmaceuticals The biopharmaceutical industry has...

AI-Powered Quality Control for Pharma Packaging

AI-Powered Quality Control in Pharmaceutical Packaging The pharmaceutical industry has...

Robotics in High-Speed Pharma Packaging Lines

Robotics and Automation in High-Speed Pharma Packaging The pharmaceutical industry...

Digital Twin Solutions for Pharma Packaging

Digital Twin Applications Optimizing Pharma Packaging Lines The pharmaceutical industry...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »